158 related articles for article (PubMed ID: 32542496)
41. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin.
Chang D; Saleh M; Gabriels J; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Epstein LM
J Am Coll Cardiol; 2020 Jun; 75(23):2992-2993. PubMed ID: 32330546
[No Abstract] [Full Text] [Related]
42. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
Taccone FS; Gorham J; Vincent JL
Lancet Respir Med; 2020 Jun; 8(6):539-541. PubMed ID: 32304640
[No Abstract] [Full Text] [Related]
43. [Not Available].
Nau JY
Rev Med Suisse; 2020 Apr; 16(N° 691-2):876-877. PubMed ID: 32348059
[No Abstract] [Full Text] [Related]
44. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.
Mehta B; Moezinia CJ; Jannat-Khah D; Gibofsky A; Tornberg H; Pearce-Fisher D; Goodman SM; Salmon JE; Ibrahim S
J Clin Rheumatol; 2020 Sep; 26(6):224-228. PubMed ID: 32694358
[TBL] [Abstract][Full Text] [Related]
45. Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia - Something to Be Concerned About?
Regazzoni V; Loffi M; Garini A; Danzi GB
Circ J; 2020 Sep; 84(10):1887. PubMed ID: 32779609
[No Abstract] [Full Text] [Related]
46. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.
Beauverd Y; Adam Y; Assouline B; Samii K
Eur J Haematol; 2020 Sep; 105(3):357-359. PubMed ID: 32324284
[TBL] [Abstract][Full Text] [Related]
47. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
Romano MR; Raimondi R; Montericcio A; Allegrini D
Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2871. PubMed ID: 32385749
[No Abstract] [Full Text] [Related]
48. [Clozapine prescription in the wake of the coronavirus (SARS CoV-2) outbreak: What measures? Why?].
Ben Dhia A; Hamzaoui S; Mouaffak F
Encephale; 2020 Jun; 46(3S):S123-S124. PubMed ID: 32317164
[No Abstract] [Full Text] [Related]
49. Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin?
Fleury V
Am J Epidemiol; 2020 Nov; 189(11):1227-1229. PubMed ID: 32685969
[TBL] [Abstract][Full Text] [Related]
50. Panic prescribing has become omnipresent during the COVID-19 pandemic.
Caplan AL; Upshur R
J Clin Invest; 2020 Jun; 130(6):2752-2753. PubMed ID: 32330122
[No Abstract] [Full Text] [Related]
51. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
Grandolfo M; Romita P; Bonamonte D; Cazzato G; Hansel K; Stingeni L; Conforti C; Giuffrida R; Foti C
Dermatol Ther; 2020 Jul; 33(4):e13499. PubMed ID: 32362051
[No Abstract] [Full Text] [Related]
52. Acute meningoencephalitis in a patient with COVID-19.
Chaumont H; Etienne P; Roze E; Couratier C; Roger PM; Lannuzel A
Rev Neurol (Paris); 2020 Jun; 176(6):519-521. PubMed ID: 32414534
[No Abstract] [Full Text] [Related]
53. Thinking Globally, Acting Locally - The U.S. Response to Covid-19.
Haffajee RL; Mello MM
N Engl J Med; 2020 May; 382(22):e75. PubMed ID: 32240580
[No Abstract] [Full Text] [Related]
54. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Avidan MS; Dehbi HM; Delany-Moretlwe S
N Engl J Med; 2020 Sep; 383(11):1087-1088. PubMed ID: 32668106
[No Abstract] [Full Text] [Related]
55. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.
Okafor EC; Pastick KA; Rajasingham R
N Engl J Med; 2020 Sep; 383(11):1089. PubMed ID: 32668109
[No Abstract] [Full Text] [Related]
56. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Tekwani BL
N Engl J Med; 2020 Sep; 383(11):1088-1089. PubMed ID: 32668108
[No Abstract] [Full Text] [Related]
57. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Khan MS; Butler J
N Engl J Med; 2020 Sep; 383(11):1088. PubMed ID: 32668107
[No Abstract] [Full Text] [Related]
58. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].
Tomcsányi J; Tomcsányi K
Orv Hetil; 2020 Apr; 161(17):689-691. PubMed ID: 32324363
[TBL] [Abstract][Full Text] [Related]
59. CNS penetration of potential anti-COVID-19 drugs.
Richardson PJ; Ottaviani S; Prelle A; Stebbing J; Casalini G; Corbellino M
J Neurol; 2020 Jul; 267(7):1880-1882. PubMed ID: 32361836
[No Abstract] [Full Text] [Related]
60. Of chloroquine and COVID-19.
Touret F; de Lamballerie X
Antiviral Res; 2020 May; 177():104762. PubMed ID: 32147496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
